Davita Inc vs Intuitive Surgical, Inc. — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Intuitive Surgical, Inc. trades at $415.78 (market cap $146.44B). The key difference: Intuitive Surgical, Inc. is far larger — about 13× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Intuitive Surgical, Inc. for 84 Days on average.
| DVA | ISRG | |
|---|---|---|
Market Cap | $11.28B | $146.44B |
Volume | 650,294 | 1,895,430 |
Sector | Health | Health |
52-Week High | $240.96 | $592.85 |
52-Week Low | $103.87 | $332.02 |
Typical Hold Time | 113 Days | 84 Days |
Enterprise Value | $24.00B | $141.22B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Intuitive Surgical (ISRG) trades at $415.41, up 2.63% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $10.06B and net income of $2.86B, maintaining impressive 28.45% net margins. Recent earnings beats and expansion into new markets like India and Japan support growth despite China headwinds. Technical indicators show the stock trading near pivot point resistance at $414 with support at $411.
ISRG presents a compelling growth story with dominant robotics positioning and expanding international footprint. The 17% selloff creates opportunity with 16% upside to consensus target of $480.78. Key risks include competitive pressures in robotic surgery and procedure growth normalization. Analyst consensus remains strongly bullish with 70% buy ratings, though valuation multiples remain elevated at P/E of 47.54.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →